問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Dermatology

Taipei Medical University Hospital (在職)

Division of Dermatology

更新時間：2023-09-19

李婉若Lee, Woan-Ruoh
  • Principal Investigator
  • Clinical Trial Experience (year) -13 years -4 個月

Recruiting Trial

25Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李婉若

List

42Cases

2025-10-01 - 2028-04-30

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2025-11-03 - 2027-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2026-01-05 - 2028-05-31

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting7Sites

2026-05-01 - 2027-12-31

Phase II

Active
A Phase 2b, Randomized, Placebo‑Controlled Study with Long-term Re-Treatment to Evaluate the Efficacy, Safety, and Tolerability of CBL‑514 Injection for Reducing Abdominal Subcutaneous Fat

  • Condition/Disease

    Subcutaneous Fat

  • Test Drug

    CBL-514

Participate Sites
8Sites

Recruiting8Sites

2025-02-01 - 2025-08-05

Completed
A multinational, multicenter, double-blind, placebo-controlled phase 2 trial evaluating the efficacy and safety of SAR444656 in adult subjects with moderate to severe atopic dermatitis.

  • Condition/Disease

    The study aimed to evaluate the efficacy of SAR444656 compared to placebo in treating AD lesions in adult subjects with moderate to severe AD. • Percentage change in EASI from baseline to week 16.

  • Test Drug

    SAR444656

Participate Sites
4Sites

Recruiting4Sites

2023-04-01 - 2031-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-09-01 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-09-01 - 2023-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting1Sites

Terminated4Sites

2026-04-01 - 2027-03-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2018-11-15 - 2020-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

李婉若
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB